Last reviewed 2026-05-25 · How we verify

METHYLPREDNISOLONE SULEPTANATE

Phase 2 active Small molecule ✓ Verified May 2026

METHYLPREDNISOLONE SULEPTANATE is a Corticosteroid drug. It is currently in Phase 2 development.

Methylprednisolone suleptanate works by binding to glucocorticoid receptors, which then suppress the expression of pro-inflammatory genes.

Methylprednisolone suleptanate is a small molecule medication. It is also known by other names, including Medrol, Promedrol, and PNU-67590A.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METHYLPREDNISOLONE SULEPTANATE
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Imagine your immune system is like a fire that gets out of control. Corticosteroids like methylprednisolone suleptanate are like fire extinguishers that help put out the flames by reducing the production of chemicals that cause inflammation. This helps to calm down the immune response and reduce swelling and pain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

METHYLPREDNISOLONE SULEPTANATE CI brief — competitive landscape report
METHYLPREDNISOLONE SULEPTANATE updates RSS · CI watch RSS

Frequently asked questions about METHYLPREDNISOLONE SULEPTANATE

What is METHYLPREDNISOLONE SULEPTANATE?

METHYLPREDNISOLONE SULEPTANATE is a Corticosteroid drug.

How does METHYLPREDNISOLONE SULEPTANATE work?

Methylprednisolone suleptanate works by binding to glucocorticoid receptors, which then suppress the expression of pro-inflammatory genes.

What drug class is METHYLPREDNISOLONE SULEPTANATE in?

METHYLPREDNISOLONE SULEPTANATE belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is METHYLPREDNISOLONE SULEPTANATE in?

METHYLPREDNISOLONE SULEPTANATE is in Phase 2.

Drug class: All Corticosteroid drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing